Brain Metastases from Primary Tumors, Volume 2 Epidemiology, Biology, and Therapy
Coordonnateur : Hayat M. A.
Brain metastases are the most common malignant tumors of the central nervous system, yet their incidence appears to be increasing in spite of the advancement of cancer therapies. While much is known about primary cancers (including primary brain tumors), less work has been done to uncover the roots of metastatic disease. Brain Metastases from Primary Tumors fills that gap, serving as the first two-part reference to focus primarily on the link between primary cancers and brain metastases. This link is explored for the most common cancer types ? lung, breast, and melanoma. Additionally, biological background as well as therapy for CNS metastases is addressed. Age- and gender-related trends are also discussed, as is the use of biomarkers for early detection.
I. GENERAL APPLICATIONS1. Brain Metastasis from Solid Tumors2. The Role of Surgical Resection for Metastatic Brain Tumors3. Whole Brain Radiotherapy for Brain Metastases: Is the Therapeutic Window Enlarging?
II. NON-SMALL CELL LUNG CANCER4. Brain Metastasis in Patients with Non-Small Cell Lung Cancer: Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor5. Brain Metastasis from Non-Small Cell Lung Cancer: Use of Egfr and Her-2 Status for Targeted Therapy6. Brain Metastases from Non-Small Cell Lung Cancer: Current Evidence in Management Using Tyrosine Kinase Inhibitor and Whole Brain Radiation Therapy7. Brain Metastasis in Patients with Non-Small Cell Lung Cancer: Immunohistochemical Markers
III. BREAST CANCER8. Brain Metastasis from Breast Cancer: Molecular Mechanisms9. New Targeted Therapies for Brain Metastasis from Breast and Lung Cancer and Melanoma10. Breast Cancers with Brain Metastases
IV. MELANOMA11. Brain Metastases in Melanoma Patients: Treatment with Adjuvant Postoperative Whole Brain Radiotherapy12. Melanoma Progression in the Brain: Role of Pericytes, the Basal Lamina, and Endothelial Cells in Tumor Vascularization
V. ESOPHAGEAL CANCER13. Brain Metastases from Esophageal Cancer in the Presence of Her-2 Overexpression
VI. RENAL CARCINOMA14. Brain Metastasis from Renal Carcinoma: Locoregional and Systemic Treatments
VII. GASTROINTESTINAL CANCER15. Gastrointestinal Cancer and Brain Metastasis Outcomes and Management
VIII. COLORECTAL CANCER16. Brain Metastasis of Colorectal Cancer: Microenvironment and Molecular Mechanism
IX. NASOPHARYNGEAL CARCINOMA17. Brain Metastasis from Nasopharyngeal Carcinoma
Academic/clinical professors, post-doctoral fellows, graduate and medical students in neuro-oncology, oncology, cancer research, pathology, reproductive oncology
- The only comprehensive reference detailing the link between primary cancers and brain metastases
- Aids the target audience in determining the incidence of brain metastases in patients with a primary cancer
- Provides education about the potential use of biomarkers for early detection, diagnosis and prevention of the spread of primary cancer to the brain
- Documents temporal and gender-related trends in brain metastases from other cancers
- Edited work with chapters authored by leaders in the field around the globe – the broadest, most expert coverage available
- The only comprehensive reference detailing the link between primary cancers and brain metastases
Date de parution : 01-2015
Ouvrage de 236 p.
19x23.3 cm
Thèmes de Brain Metastases from Primary Tumors, Volume 2 :
Mots-clés :
adjuvant whole-brain radiotherapy; anti-VEGF treatments; basal lamina; blood-brain barrier; brain metastases; brain metastasis; brain microenvironment; brain necrosis; breast cancer; caspase-3; central nervous system; chemotherapy; clinical evidence; CNS metastases; colorectal cancer; E-cadherin; EGFR deregulation; EGFR mutation; endothelial cells; epidermal growth factor receptor; esophageal carcinoma; esophagectomy; gallbladder; gastrointestinal; HER-2 overexpression; HER2 deregulation; high-resolution gene expression profiling technology; hormone therapy; human epidermal growth factor receptor 2; locoregional approach; mammalian target of rapamycin inhibitors; melanoma; melanoma vascularization; microenvironment; microvessel morphogenesis; molecular-targeted drug therapy; nasopharyngeal carcinoma; non-small cell lung cancer; non-small cell lung carcinomas; palliative benefit; pancreatic; patient selection; pericytes; prophylactic cranial irradiation; radiation oncology; radiosensitizing agents; recursive partitioning analysis; small bowel; spinal metastasis; stereotactic radiosurgery; surgical resection; targeted systemic therapies; targeted therapy; toxicity; tumor response; tyrosine kinase inhibitors; vascular endothelial growth factor; vascular endothelial growth factor receptor; whole-brain radiation therapy; whole-brain radiotherapy